Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway

Neurobiology of Aging

Volumn 21, Issue 2, 2000, Pages 183-197

  Paris, Daniel ^a   Town, Terrence ^a   Mori, Takashi ^a   Parker, Timothy A ^a   Humphrey, James ^a   Mullan, Michael ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

amyloid induced vasoactivity; Alzheimer's disease; Arachidonic acid; Cerebrovasculature; Cyclooxygenase; Inflammation; Lipoxygenase; p38 MAPK; p42 44 MAPK; Phospholipase A2; Prostaglandin; Soluble amyloid; Transgenic mice

Indexed keywords

1,6 HEXAMETHYLENEDICARBAMIC ACID BIS(CYCLOHEXANONE OXIME) ESTER; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 9 (TETRAHYDRO 2 FURYL)ADENINE; AMYLOID BETA PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BISINDOLYLMALEIMIDE; CYCLOOXYGENASE 2; DIACYLGLYCEROL; ENDOTHELIN 1; ENZYME INHIBITOR; ICOSANOID; MASTOPARAN; MELITTIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PEPTIDE; PHOSPHOLIPASE A2; QUERCETIN; SECRETORY PROTEIN; SYNAPTOPHYSIN; VASOACTIVE AGENT;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARACHIDONIC ACID METABOLISM; BRAIN; BRAIN CIRCULATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLUBILITY; SOLUBILIZATION; TRANSGENIC MOUSE; VASOCONSTRICTION;

AMYLOID BETA-PROTEIN; ANIMALS; AORTA, THORACIC; ARACHIDONIC ACID; CALMODULIN-BINDING PROTEINS; CYCLOOXYGENASE 2; EICOSANOIDS; ENDOTHELIN-1; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ISOENZYMES; MALE; MICE; PEPTIDES; PHOSPHOLIPASES A; PHOSPHOPROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION;

EID: 0034603601     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(99)00111-6     Document Type: Conference Paper

References (93)

1. Abramovitz M., Wong E., Cox M.E., Richardson C.D., Li C., Vickers P.J. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem. 215:1993;105-111.
2. Ackermann E.J., Conde-Frieboes K., Dennis E.A. Inhibition of Macrophage Ca-independent phospholipase A by bromoenol lactone and trifluoromethyl ketones. J Biol Chem. 270:1995;445-450.
3. Arita H., Hanasaki K., Nakano T., Oka S., Teraoka H., Matsumoto K. Novel proliferative effect of phospholipase A2 in Swiss 3T3 cells via specific binding site. J Biol Chem. 266:1991;19139-19141.
4. Augert G., Bocckino S.B., Blackmore P.F., Exton J.H. Hormonal stimulation of diacylglycerol formation in hepatocytes. Evidence for phosphatidylcholine breakdown. J Biol Chem. 264:1989;21689-21698.
5. Basso D., Fabris C., Panozzo M.P., Meggiato T., Del Favero G., Naccarato R. Serum phospholipase A2 activity in chronic pancreatic diseases. Clin Biochem. 23:1990;229-232.
6. 2 mediate IL-1 beta-induced camp production in human vascular smooth muscle cells. Am J Physiol. 276:1999;H1369-H1378.
7. Bhattacharyya D.K., Lecomte M., Dunn J., Morgans D.J., Smith W.L. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys. 317:1995;19-24.
8. Borsch-Haubold A.G., Pasquet S., Watson S.P. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB203580 and PD98059. SB203580 also inhibits thromboxane synthase. J Biol Chem. 273:1998;28766-28772.
9. Capdevila JH, Wei S, Yan J, Karara A, Jacobson HR, Falck JR, Guengerich FP, DuBois RN. Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem 1992;25;267:21720-6.
10. Chen G., Wood E.G., Wang S.H., Warner T.D. Expression of cyclooxygenase-2 in rat vascular smooth muscle cells is unrelated to nuclear factor-kappaB activation. Life Sci. 64:1999;1231-1242.
11. 2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 65:1991;1043-1051.
12. Coria F., Moreno A., Rubio I., Garcia M.A., Morato E., Mayor F. The cellular pathology associated with Alzheimer β-amyloid deposits in non-demented aged individuals. Neuropathol Appl Neurobiol. 19:1993;261-268.
13. Crawford F., Suo Z., Fang C., Mullan M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp Neurol. 150:1998;159-168.
14. Dean J.L., Brook M., Clark A.R., Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem. 274:1999;264-269.
15. Dennis E.A., Rhee S.G., Billah M.M., Hannun Y.A. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J. 5:1991;2068-2077.
16. Dennis E.A. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci. 22:1997;1-2.
17. Duara R., Grady C., Haxby J., Sundaram M., Cutler N.R., Heston L., Moore A., Schlageter N., Larson S., Rapoport S.I. Positron emission tomography in Alzheimer's disease. Neurology. 36:1986;879-887.
18. Dudley D.T., Pang L., Decker S.J., Bridges A.J., Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 92:1995;7686-7689.
19. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease the CERAD experience, Part XV . Neurology. 46:1996;1592-1596.
20. Farooqui A.A., Rapoport S.I., Horrocks L.A. Membrane phospholipid alterations in Alzheimer's disease deficiency of ethanolamine plasmalogens . Neurochem Res. 22:1997;523-527.
21. Fayard J.M., Tessier C., Cohen H., Lagarde M., Pageaux J.F., Laugier C. Phospholipase A2 inhibitors regulate the proliferation of normal uterine cells. Eur J Pharmacol. 251:1994;281-289.
22. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 47:1994;55-59.
23. Glover S., de Carvalho M.S., Bayburt T., Jonas M., Chi E., Leslie C.C., Gelb M.H. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem. 270:1995;15359-15367.
24. Gravitt K.R., Ward N.E., O'Brian C.A. Inhibition of protein kinase C by melittin antagonism of binding interactions between melittin and the catalytic domain by active-site binding of MgATP . Biochem Pharmacol. 47:1994;425-427.
25. Griffin W.S.T., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease significance in plaque evolution . J Neuropathol Exp Neurol. 54:1995;276-281.
26. Guan Z., Buckman S.Y., Pentland A.P., Templeton D.J., Morrison A.R. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. J Biol Chem. 273:1998;12901-12908.
27. Han S.K., Lee B.I., Cho W. Bacterial expression and characterization of human pancreatic phospholipase A2. Biochim Biophys Acta. 1346:1997;185-192.
28. Hanasaki K., Yokota Y., Ishizaki J., Itoh T., Arita H. Resistance to endotoxic shock in phospholipase A2 receptor-deficient mice. J Biol Chem. 272:1997;32792-32797.
29. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., Nguyen X., Pye Q.N., Stewart C.A., Geddes J., Markesbery W.R., Patel E., Johnson G.V., Bing G. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem. 72:1999;2053-2058.
30. Hernandez M., Burillo S.L., Crespo M.S., Nieto M.L. Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. J Biol Chem. 273:1998;606-612.
31. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
32. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., Iadecola C., Clark H.B., Carlson G. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 15:1995;1203-1218.
33. Husain S., Abdel-Latif A.A. Role of protein kinase C alpha in endothelin-1 stimulation of cytosolic phospholipase A2 and arachidonic acid release in cultured cat iris sphincter smooth muscle cells. Biochim Biophys Acta. 1392:1998;127-144.
34. Huwiler A., Staudt G., Kramer R.M., Pfeilschifter J. Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells. Biochim Biophys Acta. 1348:1997;257-272.
35. Iadecola C., Zhang F., Niwa K., Eckman C., Turner S.K., Fischer E., Younkin S., Borchelt D.R., Hsiao K.K., Carlson G.A. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 2:1999;157-161.
36. Ishizaki J., Hanasaki K., Higashino K., Kishino J., Kikuchi N., Ohara O., Arita H.J. Molecular cloning of pancreatic group I phospholipase A2 receptor. Biol Chem. 269:1994;5897-5904.
37. Itagaki S., McGeer P.L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 24:1989;173-182.
38. Iversen L.L., Mortishire-Smith R.J., Pollack S.J., Shearman M.S. The toxicity in vitro of beta-amyloid protein. Biochem J. 311:1995;1-16.
39. Iwamoto N., Kobayashi K., Kosaka K. The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients. J Neurol. 236:1989;80-84.
40. Jeandel C., Nicolas M.B., Dubois F., Nabet-Belleville F., Penin F., Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology. 35:1989;275-282.
41. Johnson K.A., Mueller S.T., Walshe T.M., English R.J., Holman B.L. Cerebral perfusion imaging in Alzheimer's disease. Use of a single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol. 44:1987;165-168.
42. Joyce-Brady M., Rubins J.B., Panchenko M.P., Bernardo J., Steele M.P., Kolm L., Simons E.R., Dickey B.F. Mechanisms of mastoparan-stimulated surfactant secretion from isolated pulmonary alveolar type 2 cells. J Biol Chem. 266:1991;6859-6865.
43. Kan H., Ruan Y., Malik K.U. Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells. Mol Pharmacol. 50:1996;1139-1147.
44. Kanemasa T., Hanasaki K., Arita H. Migration of vascular smooth muscle cells by phospholipase A2 via specific binding sites. Biochim Biophys Acta. 1125:1992;210-214.
45. Kauser K., Clark J.E., Masters B.S., Ortiz de Montellano P.R., Ma Y.H., Harder D.R., Roman R.J. Inhibitors of cytochrome P-450 attenuate the myogenic response of dog renal arcuate arteries. Circ Res. 68:(4):1991;1154-1163.
46. Kishino J., Ohara O., Nomura K., Kramer R.M., Arita H. Pancreatic-type phospholipase A2 induces group II phospholipase A2 expression and prostaglandin biosynthesis in rat mesangial cells. J Biol Chem. 269:1994;5092-5098.
47. Klinker J.F., Laugwitz K.L., Hageluken A., Seifert R. Activation of GTP formation and high-affinity GTP hydrolysis by mastoparan in various cell membranes. G-protein activation via nucleoside diphosphate kinase, a possible general mechanism of mastoparan action. Biochem Pharmacol. 51:1996;217-223.
48. Kundu G.C., Mukherjee A.B. Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J Biol Chem. 272:1997;2346-2353.
49. Kuo Y., Emmerling M., Vigo-Pelfrey C., Kasunic T.C., Kirkpatrick J.B., Murdoch G.H., Ball M.J., Roher A. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 271:1996;4077-4081.
50. Kuo Y., Emmerling M., Lampert H., Hempelman S.R., Kokjohn T.A., Woods A.S., Cotter R.J., Roher A. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's Disease. Biochem Biophys Res Comm. 257:1999;787-791.
51. Lambeau G., Ancian P., Barhanin J., Lazdunski M.J. Cloning and expression of a membrane receptor for secretory phospholipases A2. Biol Chem. 269:1994;1575-1578.
52. Lehtonen J.Y., Holopainen J.M., Kinnunen P.K. Activation of phospholipase A2 by amyloid beta-peptides in vitro. Biochemistry. 35:1996;9407-9414.
53. Li P.L., Campbell W.B. Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res. 80:1997;877-884.
54. 2 is phosphorylated and activated by MAP kinase. Cell. 72:1993;269-278.
55. Lindahl M., Tagesson C. Selective inhibition of group II phospholipase A2 by quercetin. Inflammation. 17:1993;573-582.
56. Longo W.E., Erickson B., Panesar N., Mazuski J.E., Robinson S., Kaminski D.L. The role of selective cyclooxygenase isoforms in human intestinal smooth muscle cell stimulated prostanoid formation and proliferation. Mediators Inflamm. 7:1998;373-380.
57. Lue L.F., Brachova L., Civin W.H., Rogers J. Inflammation, Abeta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 55:1996;1083-1088.
58. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 155:1999;853-862.
59. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease a review of 17 epidemiologic studies . Neurology. 47:1996;425-432.
60. McGeer P.L., McGeer E.G. Inflammation of the brain in Alzheimer's disease implications for therapy . J Leukoc Biol. 65:1999;409-415.
61. Minami T., Tojo H., Shinomura Y., Komatsubara T., Matsuzawa Y., Okamoto M. Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis. Am J Gastroenterol. 88:1993;1076-1080.
62. Morita I., Schindler M., Reiger M.K., Otto J.C., Hori T., DeWitt D.L., Smith W.L. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 270:1995;10902-10908.
63. Murakami M., Shimbara S., Kambe T., Kuwata H., Winstead M.V., Tischfield J.A., Kudo I. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem. 273:1998;14411-14423.
64. Naidu A., Quon D., Cordell B. beta-Amyloid peptide produced in vitro is degraded by proteinases released by cultured cells. J Biol Chem. 270:1995;1369-1374.
65. Nakajima M., Hanasaki K., Ueda M., Arita H. Effect of pancreatic type phospholipase A2 on isolated porcine cerebral arteries via its specific binding sites. FEBS Lett. 309:1992;261-264.
66. Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H., Wurtman R.J. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA. 89:1992;1671-1675.
67. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285:1999;1276-1279.
68. Nomura K., Fujita H., Arita H. Gene expression of pancreatic-type phospholipase-A2 in rat ovaries stimulatory action on progesterone release . Endocrinology. 135:1994;603-609.
69. Okamoto T., Takeda S., Murayama Y., Ogata E., Nishimoto I. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J Biol Chem. 270:1995;4205-4208.
70. Osanai T., Kamada T., Fujiwara N., Katoh T., Takahashi K., Kimura M., Satoh K., Magota K., Kodama S., Tanaka T., Okumura K. A novel inhibitory effect on prostacyclin synthesis of coupling factor 6 extracted from the heart of spontaneously hypertensive rats. J Biol Chem. 273:1998;31778-31783.
71. Pang L., Knox A.J. Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol. 121:1997;579-587.
72. 1-40 peptide. Exp Neurol. 152:1998;116-122.
73. Paris D., Town T., Parker T.A., Humphrey J., Mullan M. Isoform-specific vasoconstriction induced by Apolipoprotein E and modulation of this effect by Alzheimer's beta-amyloid peptide. Neurosci Lett. 256:1998;73-76.
74. Paris D., Town T., Parker T.A., Tan J., Humphrey J., Crawford F., Mullan M. Inhibition of Alzheimer's beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Exp Neurol. 157:1999;211-221.
75. Riendeau D., Guay J., Weech P.K., Laliberte F., Yergey J., Li C., Desmarais S., Perrier H., Liu S., Nicoll-Griffith D., Street I.P. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem. 269:1994;15619-15624.
76. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
77. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem. 271:1996;18295-18298.
78. Serhan C.N., Haeggstrom J.Z., Leslie C.C. Lipid mediator networks in cell signaling update and impact of cytokines . FASEB J. 10:1996;1147-1158.
79. Sisodia S.S., Price D.L. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 9:1995;366-370.
80. 2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis. 3:1996;51-63.
81. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
82. Street I.P., Lin H.K., Laliberte F., Ghomashchi F., Wang Z., Perrier H., Tremblay N.M., Huang Z., Weech P.K., Gelb M.H. Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry. 32:(23):1993;5935-5940.
83. Suo Z., Humphrey J., Kundtz A., Sethi F., Placzek A., Crawford F., Mullan M. Soluble Alzheimer's beta-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett. 257:1998;77-80.
84. Surette M.E., Dallaire N., Jean N., Picard S., Borgeat P. Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B4 in chemotactic peptide-stimulated human neutrophils. FASEB J. 12:1998;1521-1531.
85. Sutherland C.A., Amin D. Relative activities of rat and dog platelet phospholipase A2 and diglyceride lipase. Selective inhibition of diglyceride lipase by RHC 80267. J Biol Chem. 257:1982;14006-14010.
86. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380:1996;168-171.
87. Tischfield J.A. A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J Biol Chem. 272:1997;17247-17250.
88. Tohkin M., Kishino J., Ishizaki J., Arita H. Pancreatic-type phospholipase A2 stimulates prostaglandin synthesis in mouse osteoblastic cells (MC3T3-E1) via a specific binding site. J Biol Chem. 268:1993;2865-2871.
89. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F., Duhamel L., Charon D., Kirilovski J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 266:1991;15771-15781.
90. Walker D.G., Yasuhara O., Patston P.A., McGeer E.G., McGeer P.L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675:1995;75-82.
91. Wisniewski H.M., Weigel J. Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation. Acta Neuropathol (Berl.). 85:1993;586-595.
92. Wisniewski H.M., Wegiel J., Wang K.C., Lach B. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol (Berl.). 84:1992;117-127.
93. Zhu M., Gelband C.H., Moore J.M., Posner P., Summers C. Angiotensin type 2 receptor stimulation of neuronal delayed-rectifier potassium current involves phospholipase A2 and arachidonic acid. J Neurosci. 18:1998;679-686.